Testing and Diagnostics Library
Every article, presentation, spotlight, and news item we've tagged to Testing and Diagnostics.
Showing 121–144 of 314
Curve Bio strengthens clinical push with CMO hire
Curve Biosciences appointed hepatologist Dr. Amit Singal as Chief Medical Officer to advance clinical translation of its circulating DNA diagnostic platform for early organ dysfunction detection. The move signals a strategic shift from technology development toward embedding blood-based diagnostics into existing clinical workflows, beginning with liver disease where earlier intervention can measurably alter patient outcomes.
AI Platform Predicts Drug-Induced Liver Injury Before Clinical Trials
VeriSIM Life has formalized collaboration with the FDA's National Center for Toxicological Research to validate its BIOiSIM platform—a hybrid mechanistic-AI system designed to predict drug-induced liver injury and support regulatory decision-making. This partnership extends preclinical safety assessment into the regulatory domain, potentially reducing the time and cost of drug development while improving early identification of hepatotoxic compounds.
Technogym and Google Cloud expand AI fitness
Technogym and Google Cloud are integrating generative AI into fitness platforms to shift from episodic workout protocols toward continuous, anticipatory health management scaled across populations. This partnership pairs four decades of physiological performance data with advanced language models to support adherence—a persistent barrier to preventive health outcomes—while embedding technology into the daily behavioral substrate where health decisions actually occur.
Metal Homeostasis Restores Insulin Sensitivity in Diabetic Model
Telomir-Zn, an investigational compound modulating intracellular metal homeostasis, restored insulin sensitivity in a diet-induced zebrafish diabetes model, with fasting glucose returning to near-control levels and HOMA-IR declining from 10-12 to approximately 3 within 14 days. The preclinical finding demonstrates dose-dependent metabolic restoration through iron-dependent pathway modulation, with potential relevance to both metabolic and oncologic disease.
HDL Cholesterol Levels Don't Predict Heart Protection
High HDL cholesterol does not reliably predict cardiovascular protection or longevity outcomes. The relationship between HDL-C levels and actual disease risk is far weaker than traditional models suggest, requiring more nuanced assessment of lipoprotein function rather than HDL quantity alone.
Skin Biomarker Automation Accelerates Clinical Trial Cycles
Haut.AI's Clinical Studies Software automates skin biomarker measurement through standardized image capture and AI analysis, reducing clinical trial setup from 8-16 weeks to 2-3 days. The platform quantifies 48 validated skin endpoints with high repeatability (ICC 0.97-0.98) and demonstrates concordance with expert assessment whether captured on medical or consumer devices.
Sex-Specific Anellome Trajectories Track Cellular Aging Divergence
Circular DNA fragments outside the nucleus (anellomes) follow distinct sex-specific patterns across the lifespan, with different trajectories in men and women that may reflect fundamental differences in cellular aging. These patterns offer a quantifiable marker for tracking how cellular stress accumulates and resolves differently between sexes.
Formulation Specificity, Not Ingredient Alone, Predicts Epigenetic Age
In a cohort of 4,260 health-conscious individuals, delayed-release calcium-alpha-ketoglutarate combined with vitamins was associated with 1.8 years lower epigenetic age, while standard AKG and CoQ10 showed minimal or non-significant benefits. The findings suggest specificity in formulation matters more than ingredient alone, and future controlled trials are needed to establish causation.
Reproductive Behavior Buffers Genetic Aging Risk
Reproductive behaviors interact with genetic susceptibility to modulate aging trajectories, with certain lifestyle patterns amplifying or buffering age-acceleration risk in genetically predisposed individuals. This research identifies a modifiable behavioral layer that operates independently of genetic burden, suggesting that aging rate is not fixed by inheritance alone.
BioAge advances NLRP3 drug for CVD, retinal care
BioAge is advancing BGE-102, an oral NLRP3 inflammasome inhibitor, into Phase 2 trials for atherosclerotic cardiovascular disease and retinal disease based on Phase 1 data showing tolerability and reductions in inflammatory markers. NLRP3 inhibition represents a mechanistic approach to reducing systemic inflammation implicated in multiple age-related conditions.
Real-World Data Integration Accelerates Clinical Decision-Making
Atropos Health and Health Universe integrated real-world clinical data and AI decision-support tools directly into clinician workflows, enabling patient-specific insights without system switching. This partnership exemplifies how consolidated longitudinal records and AI-driven analysis can translate evidence into actionable clinical intelligence at the point of care.
AI Auditing System Tackles Longevity Evidence Hallucination
Forever Healthy released AI4L, an open-source framework that uses adversarial AI workflows and live citation verification to generate evidence-based reviews of longevity interventions while minimizing hallucination and citation fabrication. The system addresses a critical infrastructure gap in longevity science: the scalability problem of evidence synthesis in a field generating evidence faster than traditional human review can process.
Givaudan showcases AI-powered ingredient demos with Haut.AI
Givaudan and Haut.AI are demonstrating AI-powered skin visualization tools at an industry conference, allowing consumers to preview how active ingredients affect visible skin parameters. The partnership emphasizes personalized prediction of ingredient effects through generative simulation technology.
C2N Diagnostics expands Alzheimer’s blood testing to South Korea
C2N Diagnostics has launched blood-based Alzheimer's testing in South Korea through a partnership with BeauBrain Healthcare. The PrecivityAD2 test detects amyloid pathology with 91% accuracy and offers a less invasive, more accessible alternative to PET imaging for identifying cognitive impairment earlier in disease progression.
AliveCor brings AI heart diagnostics to Vietnam
AliveCor's Kardia 12L portable AI-powered ECG system has gained regulatory approval in Vietnam, enabling distributed cardiac diagnostics in a country where cardiovascular disease accounts for 33% of deaths. The device reduces acquisition time by approximately 30% and simplifies the testing process, addressing both access barriers and workflow bottlenecks in healthcare systems managing high patient volumes.
Featured Cover
Astronauts exposed to spaceflight show accelerated epigenetic aging markers during mission, with partial recovery after return to Earth. This natural experiment reveals how extreme environmental stress—microgravity, radiation, isolation—affects the molecular clock and provides insight into aging acceleration mechanisms relevant to terrestrial health conditions.
Insilico lands $5m as AI-designed drug hits first-in-human milestone
Insilico Medicine's AI-designed drug candidate MEN2501 has advanced to first-in-human dosing in a Phase 1 trial, triggering an $5 million milestone payment and validating generative AI's capacity to compress drug discovery timelines from years to months. The molecule targets chromosomal instability in solid tumors—a mechanism relevant to cellular aging—and represents a proof-of-concept for AI-driven identification of therapeutic candidates.
AI Model Unlocks Blood-Brain Barrier Drug Penetration
Frontier Bio won Phase 1 of a $7 million NIH competition for developing an AI-powered human cell model that predicts drug passage across the blood-brain barrier, potentially accelerating brain-directed longevity therapies by years while reducing reliance on animal testing.
This AI ‘virtual lab’ wants to cut drug discovery to weeks
Helical has raised $10 million to build a shared computational platform that integrates AI models with reproducible workflows for drug discovery, addressing the critical gap between predictive capability and implementable decision-making in pharmaceutical R&D. The platform consolidates fragmented AI predictions into a unified system where results are traceable, validated, and actionable at scale.
Automated brain volumetry gains EU clearance for longevity tracking
Cortechs.ai obtained expanded EU medical device certification for its NeuroQuant platform, enabling automated quantitative imaging across neurology, neuro-oncology, and prostate analysis. The certification validates a scalable framework for AI-driven tissue volumetry and longitudinal tracking in clinical practice across the European Economic Area.
Parental Age Shapes Offspring Metabolism Across the Lifespan
Parental age at conception produces sex-specific physiological effects in offspring that persist into adulthood, with paternal age showing stronger effects on male offspring metabolism and stress response. These findings in a long-lived seabird model suggest that inherited physiological patterns from parents may constrain or enable longevity trajectories independent of direct genetic mutation.
Cognito and Ochsner launch brain health collaboratory
Cognito Therapeutics and Ochsner Health have established a regional platform to evaluate Spectris, a non-invasive device that uses synchronized light and sound to stimulate gamma-frequency brain activity, alongside clinical infrastructure to assess its effectiveness in cognitive decline and Alzheimer's disease. The collaboratory will generate real-world data on treatment response, cost-effectiveness, and scalability across diverse populations.
Nanotech startup lands funding for continuous biosensing platform
Xsensio has secured $7 million in Series A funding to advance a wearable biosensing platform that continuously monitors multiple biomarkers in interstitial fluid, initially targeting early detection of organ dysfunction in acute care settings. Real-time access to biochemical data at the point of care represents a shift from periodic laboratory measurement to continuous physiological surveillance, with potential implications for earlier clinical intervention.
Argo pushes gene-silencing therapy for heart risk into Phase 2b
Argo Biopharma has dosed the first patient in a Phase 2b trial of BW-20829, an siRNA therapy targeting elevated Lipoprotein(a) and atherosclerotic cardiovascular disease. Lp(a) represents a genetically determined cardiovascular risk factor resistant to conventional interventions, making this advance relevant to a significant gap in current therapeutic options for reducing disease burden and extending healthspan.